Poland· PL-100485378

Omvoh

A mirikizumab product containing mirikizumabum, registered in Poland by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L04AC24

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOmvohATCL04AC24REGISTER NO.PL-100485378PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Mirikizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Mirikizumab · ATC L04AC24

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mirikizumab costs, country by country.

Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mirikizumab · price per daily dose (7.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$30.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Mirikizumabum
Manufacturer
Eli Lilly Nederland B.V.
Country
Poland (PL)
ATC code
L04AC24
ATC class
Mirikizumab
Defined daily dose
7.1 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05999885490202

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4fffb18f-a865-497b-a953-895798bcba7a
GET /v1/drugs/4fffb18f-a865-497b-a953-895798bcba7a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "300 mg/15 ml",
  "packaging": "05999885490202 ¦ Rpz ¦ EU/1/23/1736/001 ¦ 150657\n1 fiol. 15 ml\nRpz ¦ EU/1/23/1736/011 ¦ 162239\n3 fiol. 15 ml",
  "substance": "Mirikizumabum 300 mg/15 ml",
  "common_name": "Mirikizumabum",
  "pl_product_id": "100485378",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about mirikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.